Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.
No articles found.
CytoDyn is a publicly traded late stage biotechnology company developing innovativ...
CytoDyn is a publicly traded late stage biotech...
Maternova, Inc. is the trusted resource for cutting edge medical innovations in ne...
Maternova, Inc. is the trusted resource for cut...
TransMedics is a commercial-stage medical technology company transforming organ tr...
TransMedics is a commercial-stage medical techn...
Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet...
Theratechnologies (TSX: TH) is a specialty phar...
China Biologic Products Holdings, Inc. (NASDAQ: CBPO), is a leading fully integrat...
China Biologic Products Holdings, Inc. (NASDAQ:...
Hoth Therapeutics is a development stage biopharmaceutical company focused on prop...
Hoth Therapeutics is a development stage biopha...
MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiri...
MediciNova, Inc. is a publicly-traded biopharma...
Neon Therapeutics is a clinical-stage immuno-oncology company leading in the field...
Neon Therapeutics is a clinical-stage immuno-on...
Join the National Investor Network and get the latest information with your interests in mind.